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Zusammenfassung 
 
Die Infusion von Glucagon-Like Peptide-1 in die Pfortader reduziert die Mahlzeitgrösse 
und erhöht die Expression von c-Fos im Nucleus tractus solitarii, in der Area postrema 
und im Zentralkern der Amygdala bei Ratten 
 
Kürzlich berichteten wir, dass kurze, ferngesteuerte Infusionen von Glucagon-Like Peptide-1 
(GLP-1) in die Pfortader von Ratten während einer Mahlzeit die spontane Mahlzeitengrösse 
reduzieren. Um die verhaltensneurologischen Wechselwirkungen dieses Effekts zu 
untersuchen, implantierten wir männlichen Sprague-Dawley Ratten Pfortaderkatheter und 
erfassten den Einfluss von ferngesteuerten Infusionen von GLP-1 (1 nmol/kg, 5 min) oder 
Kontrolllösung auf den Verzehr während der ersten Mahlzeit in der Dunkelphase nach 3h 
Futterentzug. Ferner erfassten wir den Einfluss analoger GLP-1 Infusionen am Beginn der 
Dunkelphase auf die c-Fos Expression in mehreren Gehirnarealen, welche in die Steuerung 
des Verzehrs involviert sind. GLP-1 reduzierte (P < 0.05) die Grösse der ersten Mahlzeit in 
der Dunkelphase und steigerte deren Sättigungsquotienten (Dauer des nachfolgenden 
Mahlzeitenintervals [min]/Mahlzeitgrösse [g]). Ebenso vermehrte (P < 0.05) GLP-1 die 
Anzahl der c-Fos exprimierenden Zellen im Nucleus tractus solitarii, in der Area postrema 
und im Zentralkern der Amygdala, nicht aber im  Nucleaus arcuatus oder im Nucleus 
paraventricularis des Hypothalamus. Diese Daten lassen darauf schliessen, dass der Nucleus 
tractus solitarii, die Area postrema und der Zentralkern der Amygdala für den 
verzehrshemmenden Effekt von GLP-1 nach Infusion in die Pfortader eine Rolle spielen. Es 
bleibt festzustellen, ob die Aktivierung dieser Hirnareale Sättigung, Aversion oder beides 
reflektiert. 
 
Schlüsselwörter: Verzehr, Sättigung, intestinales Peptid, Hinterhirn, Aversion 
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ORIGINAL ARTICLE
Hepatic-Portal Vein Infusions of Glucagon-Like Peptide-1 Reduce Meal
Size and Increase c-Fos Expression in the Nucleus Tractus Solitarii, Area
Postrema and Central Nucleus of the Amygdala in Rats
I. Baumgartner, G. Pacheco-Lo´pez, E. B. Ru¨ttimann, M. Arnold, L . Asarian, W. Langhans, N. Geary and J. J. G. Hillebrand
Physiology and Behaviour Laboratory, Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland.
Glucagon-like peptide-1-(7-36)-amide (GLP-1) is synthesised and
released by L-cells in the distal ileum and colon and by a small
population of neurones in the nucleus tractus solitarii (NTS) (1, 2).
GLP-1 receptors (GLP-1R) are widely expressed both in the brain
and in the periphery, where they are found in the gastrointestinal
tract, pancreatic islets, portal vein, liver and vagus nerve (1, 2).
GLP-1 is considered to have a range of physiological actions,
including stimulation of insulin secretion (i.e. an incretin effect)
(1, 2), inhibition of glucagon secretion (1, 3), inhibition of gastro-
intestinal secretory and motor functions (i.e. ileal brake effect) (4),
control of autonomic and behavioural stress and aversion responses
(5, 6) and inhibition of eating (1, 6–8).
The effects of GLP-1 on eating include specific reductions in
meal size (‘satiation’) (5, 8–11) and nonspecific anorexia (e.g. the
anorexia produced by the visceral malaise that both directly inhibits
eating and leads to the formation of conditioned taste aversions)
(5, 10, 12–15). The conditions under which (endogenous) GLP-1
produces satiation or malaise-related anorexia, and the relative
contributions of peripheral and central GLP-1 and GLP-1R to these
actions, remain unclear. Perhaps the strongest evidence that
peripheral GLP-1 can have a specific satiating effect comes from
the observations that i.p. administration of the GLP-1 antagonist
exendin (9–39) acutely increased eating in rats under some condi-
tions (11) and that i.v. infusion of physiological doses of GLP-1 (i.e.
doses that mimic the increase in endogenous GLP-1 following
meals) were sufficient to decrease food intake in humans without
side effects (7, 16).
Recent findings from our laboratory indicate that peripheral GLP-1
acts at two different sites to inhibit eating in rats (9). In tests of brief,
remotely controlled, infusions of 10 nmol ⁄ kg (33 lg ⁄ kg) GLP-1
during spontaneous meals, the eating-inhibitory effect of i.p.
infused GLP-1 depended on intact abdominal vagal afferents,
whereas the effect of hepatic-portal vein (HPV) infusions of GLP-1
did not. These data demonstrate that vagal afferent signalling is
not necessary for the eating-inhibitory effect of HPV GLP-1 and are
consistent with the idea that i.p. GLP-1, perhaps similar to endoge-
nous GLP-1, inhibits eating by activating GLP-1R on vagal afferents
terminating in the lamina propria of the intestinal mucosa. We also
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We recently reported that brief, remotely controlled intrameal hepatic-portal vein infusions of
glucagon-like peptide-1 (GLP-1) reduced spontaneous meal size in rats. To investigate the
neurobehavioural correlates of this effect, we equipped male Sprague-Dawley rats with hepatic-
portal vein catheters and assessed (i) the effect on eating of remotely triggered infusions of
GLP-1 (1 nmol ⁄ kg, 5 min) or vehicle during the first nocturnal meal after 3 h of food depriva-
tion and (ii) the effect of identical infusions performed at dark onset on c-Fos expression in sev-
eral brain areas involved in the control of eating. GLP-1 reduced (P < 0.05) the size of the first
nocturnal meal and increased its satiety ratio. Also, GLP-1 increased (P < 0.05) the number of
c-Fos-expressing cells in the nucleus tractus solitarii, the area postrema and the central nucleus
of the amygdala, but not in the arcuate or paraventricular hypothalamic nuclei. These data sug-
gest that the nucleus tractus solitarii, the area postrema and the central nucleus of the amyg-
dala play a role in the eating-inhibitory actions of GLP-1 infused into the hepatic-portal vein; it
remains to be established whether activation of these brain nuclei reflect satiation, aversion, or
both.
Key words: eating, satiation, gut peptide, hindbrain, aversion.
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observed that HPV GLP-1 infusions failed to inhibit eating more
potently than vena caval infusions of the same GLP-1 dose, indicat-
ing that the GLP-1R mediating the eating-inhibitory effect of HPV
GLP-1 are not located in the HPV area or in the liver. A recent
study finding that GLP-1 inhibited eating more after intrajugular
than after HPV infusion also supports this interpretation (17). Taken
together, these data suggest that circulating GLP-1 may act on
GLP-1R in the brain to inhibit eating.
Brain areas involved in processing of satiation signals are com-
monly investigated using c-Fos immunohistochemistry (IHC). As
reviewed below, there are few studies associating the effects of
GLP-1 on eating and c-Fos expression. In particular, the effects of
i.v. administration of GLP-1 on c-Fos expression in the brain have
not been characterised. Therefore, in the present study we aimed
to determine the effects of HPV infusion of 1 nmol ⁄ kg GLP-1, a
moderate dose that reliably reduced spontaneous meal size under
our conditions (9), on neural activation, as measured by c-Fos IHC,
in several brain areas involved in the control of eating.
Materials and methods
Subjects and housing
Male Sprague-Dawley [Crl:CD (SD)] rats (Charles River, Sulzfeld, Germany),
weighing 180–200 g body weight upon arrival, were individually housed in
acrylic infusion cages [21 · 37 · 41 cm, length (l) · width (w) · height (h)]
with stainless steel grid floors under a 12 : 12 h dark ⁄ light cycle (lights off
12.00 h) in a climate-controlled room (22  2 C and 60% relative humid-
ity). Ground chow (3433; Provimi Kliba SA, Kaiseraugst, Switzerland) was
available in food cups that were accessible in a niche [5 · 7 · 30 cm
(l · w · h)], 6 cm above the cage floor, on one side of the cage. Tap water
was available ad lib. A 60-W red incandescent light bulb provided dim illu-
mination during the dark phase, and a radio tuned to a music station was
played continuously to mask extraneous noise. All protocols were approved
by the Veterinary Office of the Canton of Zurich.
Catheter implantation and patency checks
Two weeks after arrival, chronic HPV infusion catheters were implanted in
all rats, as described previously (9). Catheters were flushed with 0.2 ml of
0.9% sterile saline and filled with 80 ll of heparinised saline (100 IU hepa-
rin ⁄ml saline; Heparin; Braun, Melsungen, Germany) daily the first week
after surgery and every 3 days thereafter. Catheter patency was verified
by infusing 0.8 ml ⁄ kg body weight of a mixture of 26 mg ⁄ kg ketamine
(Ketasol-100; Dr E. Gra¨ub AG, Bern, Switzerland) and 0.9 mg ⁄ kg xylazine
(Rompun; Bayer, Leverkusen, Germany) at the end of behavioural tests.
The criterion for catheter patency was a complete loss of muscle tone
within 1 min. In addition, in Experiment 2, 0.5 ml of Giemsa stain (Sigma-
Aldrich, Buchs, Switzerland) was infused into the HPV after laparotomy, and
the perfusion of the HPV with blue stain without leakage was verified. In
Experiment 2, the criteria for catheter patency were that both the anesthesia
test and the Giemsa stain tests be successful. Data from rats without patent
HPV catheters were not included in the analyses.
Experiment 1: eating
Tests began 2 weeks after surgery. Food cups were mounted on electronic
balances (XS4001S; Mettler-Toledo, Greifensee, Switzerland) linked to a com-
puter that sampled the weight of each balance every 30 s. Meal patterns
were analysed with custom-made software (LabX-Meal-analyzer 1.4; Met-
tler-Toledo). In addition, rats were monitored with infrared video cameras
(Conrad Electronic GmbH, Hirschau, Germany). A meal was defined as a
decrease of > 0.3 g in food cup weight and visual verification of eating.
Experimenters in an adjacent control room monitored the balance weights
and rats’ behaviour and triggered the infusions by remote control. Twelve
rats (body weight = 346  4 g) were adapted to the following procedure
for several days: (i) 08.15 h, weigh rats; (ii) 09.00 h, remove food; (iii)
11.00 h, attach HPV catheters to the infusion pumps as described previously
(9); (iv) 12.00 h, offer fresh ground chow; (v) 2 min after the onset of the
first meal, start HPV infusion (0.2 ml ⁄min for 5 min) of 1 nmol ⁄ kg GLP-1(7-
36)-amide (Bachem, Bubendorf, Switzerland) dissolved in phosphate-buffered
saline (PBS) with 1% bovine serum albumin (Sigma-Aldrich) or vehicle; and
(vi) 16.00 h, disconnect rats from infusion pumps and flush catheters. GLP-1
and vehicle were tested on consecutive days using a within-subjects cross-
over design.
Experiment 2: c-Fos immunohistochemistry
Sixteen rats underwent similar surgical procedures as for Experiment 1. Two
weeks after surgery, rats were adapted to the infusion protocol and to a
19-h feeding – 5-h (09.00–14.00 h) food deprivation schedule. The experi-
ment was performed after a few weeks of adaptation, when rats weighed
442  11 g. GLP-1 (1 nmol ⁄ kg body weight, n = 9) or vehicle (n = 7) was
infused (0.2 ml ⁄min, 5 min) at the onset of dark (12.00 h, food was not
returned) and, 90 min later, rats were deeply anesthetised with an i.p. injec-
tion of 100 mg ⁄ kg body weight sodium pentobarbital (Cantonal Pharmacy,
Zurich, Switzerland) and transcardially perfused with PBS (0.1 M, pH 7.2)
followed by 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield,
PA, USA). Infusions and perfusions were performed at 5-min intervals within
25 min of the times given above. Brains were excised and post-fixed over-
night at 4 C, then switched to 30% sucrose in 0.1 M PBS, and kept at 4 C
until processing.
Brains were sectioned using a freezing sliding microtome (Microm
International, Walldorf, Germany) and 40-lm sections were collected and
stored in 0.1 M PBS with 0.1% sodium azide (Fluka, Buchs, Switzerland) at
4 C. Every sixth section of the forebrain (i.e. each 240 lm) and every
twelfth section of the hindbrain (i.e. each 480 lm) were processed for
c-Fos using a standard single-label indirect IHC technique (18). Briefly,
after endogenous peroxidase quenching (0.5% H2O2, 0.1 M PBS, 30 min, at
room temperature; RT), and blocking nonspecific interactions and perme-
abilisation (5% normal goat serum, 0.1 M PBS, 0.3% Triton-X, 1 h, RT),
brain sections were incubated with primary antibody (1 : 2500 rabbit anti-
c-Fos; 72 h, 4C, sc-52; Santa Cruz Biotech., Santa Cruz, CA, USA). After-
wards, sections were incubated with a secondary biotinylated antibody
(1 : 200 goat anti-rabbit IgG; 2 h, RT; Vector Laboratories, Burlingame, CA,
USA). The antibody complex was visualised by allowing the streptavidin-
diaminobenzidine (DAB)-peroxidase (ABC kit; Vector Laboratories) to react
with the DAB-tetrahydrochloride substrate (5 min, RT; Sigma-Aldrich). All
incubation steps were performed on an orbital shaker at approximately
250 Hz, and several interim rinse steps were performed throughout the
procedure. Sections were then mounted on gelatin-coated slides, dehy-
drated in an increasing series of alcohols, defatted in xylene, and cover-
slipped with Permount (Menzel, Braunschweig, Germany). Photomicro-
graphs were digitally acquired under · 20 magnification and bright-field
illumination using an Olympus AX-70 microscope (Olympus, Center Valley,
PA, USA) connected to a digital colour camera interfaced to a computer.
Photomicrographs were assigned to the nearest anterior-posterior bregma
level according to a rat brain atlas (19), and c-Fos-positive cells were
counted within the regions of interest (ROI). Transparencies made from
the brain atlas were used to delineate ROI at the closest anterior-poster-
ior level, and cell counting was performed using VOLOCITY 4 software
558 I. Baumgartner et al.
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(Improvision, Coventry, UK; settings: 65–85 % of intensity, 30 lm2
< object size > 200 lm2), operated by an experimenter who was blind to
the treatments. Brain structures counted were: NTS (six sections between
13.08 and 15.48 mm posterior to bregma), area postrema (AP; one section
at approximately 14.04 mm posterior), central nucleus of the amygdala
(CeA; eight sections between 1.56 and 3.24 mm posterior), arcuate nucleus
(nine sections between 1.72 and 3.64 mm posterior), and hypothalamic
paraventricular nucleus (PVN; eight sections between 0.72 and 2.04 mm
posterior).
Statistical analysis
Meal sizes (first and second) during the test period, intermeal interval (IMI)
(duration between the end of the first meal and the start of the second
meal), and first meal satiety ratio (IMI ⁄ first meal size) were analysed with
paired-sample t-tests using SPSS, version 16.0 (SPSS Inc., Chicago, IL, USA).
c-Fos-positive cell counts in the anterior-posterior regions of the NTS, CeA,
arcuate nucleus and PVN in which c-Fos-positive cells were detected were
analysed by two-way ANOVA with treatment (GLP-1, vehicle) and bregma level
as factors. Significant ANOVA interaction effects were followed-up with Bon-
ferroni-Holm contrasts (20) between GLP-1- and vehicle-treated rats at each
bregma level. Because only one section in the AP was counted, c-Fos-posi-
tive cells in this area were analysed using an independent-sample t-test. To
increase statistical power, data were converted to standard scores using the
median absolute deviate method (21). Extreme values, defined as standard
scores with absolute values > 1.96 (i.e. P < 0.05), were excluded. The inci-
dence of such values was: NTS, 5%; AP, 13%; CeA, 23%; arcuate nucleus,
17%; and PVN 10%. A nonparametric reanalysis of the complete data sets
yielded the same effects as the post-hoc parametric analysis. Data are pre-
sented as the mean  SEM, and the standard error of the difference (SED)
is given as a measure of residual error variability. P < 0.05 was considered
statistically significant.
Results
Experiment 1: eating
HPV infusions of 1 nmol ⁄ kg GLP-1 reduced the size of the first
meal (t8 = 2.82, P = 0.02, SED = 0.6 g) (Fig. 1A) and increased the
first meal satiety ratio (t8 = 4.16, P = 0.003, SED = 3.8 min ⁄ g) ver-
sus vehicle treatment (Fig. 1B). The IMI between the first and sec-
ond meals (t7 = 0.34, P > 0.05, SED = 17 min) and the size of the
second meal (t7 = 1.39, P > 0.05, SED = 0.6 g) were not signifi-
cantly affected by GLP-1 (Fig. 1C, D). The analyses were performed
on ten rats that passed the catheter patency test.
Experiment 2: c-Fos immunohistochemistry
HPV GLP-1 infusion increased the number of c-Fos-positive cells in
the NTS between 13.08 and 14.52 mm posterior to bregma (interac-
tion effect: F3,36 = 4.06, P < 0.001, SED = 10 cells ⁄ section),
although post-hoc tests detected a significant difference between
GLP-1- and vehicle-treated rats only at 14.04 mm posterior to
bregma (Fig. 2A). HPV GLP-1 infusion significantly increased the
number of c-Fos-positive cells in the AP at this level as well
(Fig. 2B; t11 = )2.63, P = 0.02, SED = 28 cells ⁄ section). Representa-
tive examples of c-Fos staining in the NTS and AP are given in
Fig. 2(C, D).
HPV GLP-1 infusion also increased the number of c-Fos-positive
cells in the CeA between 2.28 and 3.24 mm posterior to bregma,
which reached statistical significance at 2.52 and 3.00 mm posterior
to bregma (Fig. 3A; treatment effect: F1,13 = 8.78, P = 0.006, bregma
level effect: F5,44 = 8.78, P < 0.001, SED = 15 cells ⁄ section). A sig-
nificant interaction effect was found for the number of c-Fos-posi-
tive cells in the arcuate nucleus (F8,81 = 3.13, P < 0.001,
SED = 9 cells ⁄ section). Post-hoc tests detected significant differ-
ence only at 3.16 mm posterior to bregma, which was probably the
result of an unusually high number of c-Fos-positive cells in vehi-
cle-treated rats because no such trend was observed in the adja-
cent sections (Fig. 3B). Finally, HPV GLP-1 infusion did not affect
the number of c-Fos-positive cells in the PVN (Fig. 3C). More c-Fos-
positive cells were found at posterior levels of the PVN (bregma
level effect: F6,67 = 13.30, P < 0.001, SED = 12 cells ⁄ section),
although there was no reliable treatment or interaction effect.
c-Fos expression analyses were performed on fifteen rats that
passed the catheter-patency tests. Representative examples of
c-Fos staining in the CeA, arcuate nucleus and PVN are given in
Fig. 3(D–I).
Discussion
The main novel finding of the present study is that the satiating
action of intrameal HPV infusion of 1 nmol ⁄ kg GLP-1 in rats is
associated with increased expression of c-Fos in the NTS, AP and
CeA, but not in the arcuate nucleus or PVN.
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Fig. 1. Intrameal hepatic-portal vein infusions of 1 nmol ⁄ kg glucagon-like
peptide-1 (GLP-1) reduced the size of the first meal compared to vehicle
infusions (A), but not of the second meal (B). The intermeal interval between
the first and the second meal was not affected by GLP-1 (c), but the first
meal satiety ratio was increased (D). Values are the mean  SEM of ten rats.
*P < 0.05.
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The specific neuronal activation pattern reported here has not
been observed in previous studies of the effects of peripheral
administration of GLP-1 or GLP-1R agonists. That is, we found more
activation than some previous studies using comparably low doses
of GLP-1 administered via different routes (22–24) and less activa-
tion than several studies using much larger doses (25, 26) or long-
lasting GLP-1 agonists (22, 27, 28). For example, Yamamoto et al.
(27) reported that femoral vein infusion of 0.24 nmol ⁄ kg (1 lg ⁄ kg)
of the potent GLP-1 agonist exendin (4–39) (Ex-4) increased c-Fos
in the NTS, AP, PVN, arcuate nucleus and other areas. It is unlikely,
however, that these effects of Ex-4 are directly comparable with
what might be produced by HPV infusion of the GLP-1 dose that we
used because GLP-1 is rapidly degraded by dipeptidyl peptidase IV,
whereas Ex-4 is resistant to this enzyme and has several orders of
magnitude greater biological activity than GLP-1 (29–31). For the
same reason, the effects of long-acting GLP-1-albumin conjugates
on c-Fos expression (22) are also of questionable relevance. There
are two reports of the effects of i.p. injections of GLP-1 doses simi-
lar to ours in rats. Rowland et al. (23) reported that i.p. injection of
7.6 nmol ⁄ kg GLP-1 did not significantly increase c-Fos expression in
the AP, PVN, arcuate nucleus or bed nucleus of the stria terminalis,
and Neary et al. (24) failed to detect increases in c-Fos expression in
the NTS, AP, PVN or arcuate nucleus after i.p. injection of
10 nmol ⁄ kg GLP-1. A higher i.p. dose, 100 nmol ⁄ kg GLP-1, did sig-
nificantly increase neuronal activation in the arcuate nucleus in rats
(25) and in the NTS, arcuate nucleus and PVN in mice (26). Another
study in mice (32), however, failed to detect increases in c-Fos
expression in these areas or in the ventromedial hypothalamus,
supraoptic nucleus or CeA after i.p. injection of 900 nmol ⁄ kg GLP-1.
It appears, therefore, that the effects of GLP-1 on c-Fos expression
depend critically on the dose, route of administration, test condi-
tions and, perhaps, species. In addition, as described above, i.p. and
HPV GLP-1 infusions inhibit eating by recruiting different mecha-
nisms (9), which may lead to differential central processing and,
hence, differential neuronal activation.
The pattern of brain c-Fos expression after HPV GLP-1 that we
observed resembles, in some respects, the effects of physiological
satiation and, in other respects, the effects of more pharmacologi-
cal treatments, including treatments that probably elicit some
degree of visceral malaise, but is not identical to either. The pattern
of increased c-Fos expression in the NTS, AP and CeA following
HPV GLP-1 resembles the neuronal activation pattern after eating.
Several studies in rats indicate that eating small amounts of food
increases c-Fos expression in the NTS, CeA and PVN, but not in the
AP (33–36). Eating larger amounts of food (e.g. in response to over-
night food deprivation), however, recruits additional c-Fos expres-
sion in these areas and can lead to increased c-Fos expression in
the AP (37, 38). Thus, the results obtained in the present study,
with the exception of the lack of an increase in c-Fos expression in
the PVN, are consistent with the hypotheses that HPV infusion of
1 nmol ⁄ kg GLP-1 has a similar effect in the brain as ingestion of a
large meal and, by extension, that such meal-stimulated effects
may be mediated by GLP-1 secretion. Very large meals, of course,
may induce visceral malaise as well as satiation, as discussed by
Rinaman et al. (37) and Verbalis et al. (39). Finally, the lack of
effect of GLP-1 on c-Fos expression in the PVN may indicate that
the eating-related feedback information encoded by GLP-1 under
our conditions does not include information sufficient to activate
the PVN, but further work would be required to confirm this.
Tests of other satiation signals provide further insight into the
potential meaning of the pattern of c-Fos expression following HPV
infusion of 1 nmol ⁄ kg GLP-1. For example, in a dose–response
study of i.p. injected cholecystokinin (CCK-8), an intestinal peptide
satiation signal, on c-Fos expression in the NTS (39), i.p. injection of
£ 2 lg ⁄ kg CCK-8 failed to elicit c-Fos expression in the AP,
whereas i.p. injection of ‡ 8 lg ⁄ kg CCK-8 clearly did. Importantly,
doses of ‡ 8 lg ⁄ kg CCK-8 usually produce aversive effects (35).
A study involving i.p. injection of 5 lg ⁄ kg amylin under a number
of conditions (40) may be similarly interpreted: 5 lg ⁄ kg amylin
failed to elicit c-Fos expression in the AP in ad lib fed rats, but did
elicit c-Fos expression in 24 h-fasted rats, which presumably is a
more stressful situation. The association of increased AP c-Fos
expression after larger versus smaller meals, larger versus smaller
doses of CCK, and more versus less stressful situations are all con-
sistent with the hypothesis that our treatment, HPV infusion of
1 nmol ⁄ kg GLP-1, may have produced some degree of visceral mal-
aise or developing malaise. It is important to note, however, that
because large, voluntary meals are one of the stimuli that produce
a pattern of c-Fos expression including increased c-Fos expression
in the AP, it is entirely likely that, under some conditions, GLP-1
and other eating-related feedback signals may produce both satia-
tion and mild malaise, and that the two phenomena need not be
mutually exclusive. GLP-1-expressing neurones in the caudal hind-
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Fig. 2. Hepatic-portal vein infusions of 1 nmol ⁄ kg glucagon-like peptide-1
(GLP-1) (filled symbols) increased the number of c-Fos-positive cells in the
nucleus tractus solitarii (NTS) (A) and area postrema (AP) (B) compared to
vehicle (open symbols) infusions. Values are the mean  SEM of 15 rats.
*P < 0.05. Representative examples of c-Fos staining in the NTS and AP
at 14.04 mm posterior to bregma in a GLP-1-treated (C) and vehicle-treated
(D) rat are presented. Scale bar = 250 lm.
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brain, which also abundantly express GLP-1R, are interesting to
consider in this context. Rinaman (41) reported that acute visceral
malaise produced by treatments such as i.p. injection of LiCl elicited
c-Fos expression in caudal hindbrain GLP-1 neurones, but that very
large meals (approximately 30 ml) that produced robust c-Fos
expression in the AP did not. On the other hand, it appears that
gastric distension-induced activation of hindbrain GLP-1 neurones
has a role in normal satiation (42, 43), likely including satiation
after large meals. Finally, Gaykema et al. (44) reported a dissocia-
tion of the effects of satiation and malaise on activation of GLP-1
neurones: ingestion of a liquid meal induced c-Fos expression in
NTS GLP-1 neurones, but not in the GLP-1 neurones in the ventro-
lateral medulla or adjacent reticular formation, whereas i.p. injec-
tion of 100 lg ⁄ kg LPS produced the opposite pattern. A dose–
response study of the effects of HPV GLP-1 on eating and c-Fos
expression in hindbrain GLP-1 neurones would help to determine
the role of endocrine GLP-1 in these pathways.
Although we have emphasised the eating-inhibitory actions of
GLP-1 here, it is entirely possible that some or all of the c-Fos
expression that we observed is related to other functions of GLP-1.
In particular, GLP-1R in the hepatic-portal area have been impli-
cated in the increases in post-prandial insulin secretion and glucose
clearance that are mediated by neural reflexes with vagal or
spinal-visceral afferent arms (9, 45, 46). Because both vagal and
spinal-visceral afferents project to the NTS, it is possible that the
increase in c-Fos expression we observed in the NTS after HPV infu-
sions of GLP-1 was related to this function rather than to the con-
trol of eating.
Finally, it is worth noting that our eating data extend the data
reported by Ru¨ttimann et al. (9). Here, GLP-1 was HPV infused in rats
re-fed at dark onset after 3 h of food deprivation and, under these
conditions, GLP-1 reduced meal size and also increased the satiety
ratio, whereas, previously (9), HPV GLP-1 infusions during truly spon-
taneous meals early in the dark phase reduced only meal size.
In conclusion, we have shown that GLP-1 infused via the HPV in
a dose that reduced meal size increased c-Fos expression in the
NTS, AP and CeA, suggesting a role for these brain areas in the eat-
ing-inhibitory action of GLP-1. Whether these effects on c-Fos
expression reflect the activation of neural networks related to satia-
tion or aversion, or both, the neurochemical phenotypes of the acti-
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vated cells, and their electrophysiological characteristics require fur-
ther research.
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